Danish drugmaker Novo Nordisk's patent on semaglutide, which is the key ingredient of weight-loss drugs, expired on March 20, paving the path for Indian drugmakers to make cheaper alternatives. Over 40 drugmakers are expected to launch 50 such medicines within weeks to compete with Ozempic and Wegovy. The prices could eventually come down to ₹1,500-2,500, HT reported.